MedTrace Logo

Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment

NCT00445120 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-01-29

No results posted yet for this study

Summary

This interventional study aims to evaluate the efficacy of oral administration of Lactobacillus Rhamnosus GG in preventing relapses of ocular inflammation in Vernal Keratoconjunctivitis (VKC) patients.

Conditions

  • Vernal Keratoconjunctivitis

Interventions

DRUG

Lactobacillus Rhamnosus GG

patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months

DRUG

placebo (sugar)

Placebo will be administered to patients once daily for six months

Sponsors & Collaborators

  • University of Genova

    collaborator OTHER

  • University of Padova

    collaborator OTHER

  • Campus Bio-Medico University

    lead OTHER

Principal Investigators

  • Stefano Bonini, MD · University Campus Bio-Medico

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-09-30
Completion
2009-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00445120 on ClinicalTrials.gov